Manufacturer record

Baroque Pharmaceuticals Pvt. Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

2 batches manufactured by Baroque Pharmaceuticals Pvt. Ltd (Gujarat) were declared Not of Standard Quality between November 2023 and November 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

2 records linked to Baroque Pharmaceuticals Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
2Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Nov 2023 to Nov 2023

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

2
NSQ batches since 2023
2
Products affected
Assay
Most common failure
Nov 2023
Latest alert

Flagged batches per year

2023 · 2

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Paracetamol & Tramadol Hydrochloride Tablets (PAAR-TM) G012221Mfg 2022-08 · Exp 2025-07 Uniformity of Dispersion & Assay of Tramadol HydrochlorideAssay CDL KolkataCDSCO lab Nov 2023
DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE & CHLORPHENIRAMINE MALEATE SYRUP G013207Mfg 2023-07 · Exp 2025-06 Assay of Phenylephrine HydrochlorideAssay CDL KolkataCDSCO lab Nov 2023

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.